Chenguang Biotech Group

SZSE:300138

Китай / Производители товаров масс. потребления / Продукты питания

Обзор

Дивиденды

Финансовая отчетность за 5 лет

Цена акций

9,52 CNY


Key Metrics	Latest
Total Revenue	6,927 B
Adjusted EBITDA	347,7 M
EBITDA Margin	5,0%
Net Profit Margin	2,6%
Total Assets	7,75 B
Total Debt	4,039 B

5Y Historical Financial Statements

Summary Financials


Summary Financials

	Fiscal Year Ending					Latest	Year-to-date Ending
(in millions)	Dec-19	Jan-21	Dec-21	Dec-22	Dec-23	12 Months	Sep-23	Sep-24

Revenue	3,265.23	3,912.94	4,873.61	6,295.87	6,871.52	6,927.50	5,169.44	5,225.43
% Growth		0.20	0.25	0.29	0.09			0.01

Adjusted EBITDA	333.83	490.59	509.67	593.27	697.40	347.65	538.22	188.47
% Margin	0.10	0.13	0.10	0.09	0.10	0.05	0.10	0.04

Adjusted EBIT	245.03	378.30	379.05	448.71	552.84	311.51	429.80	188.47
% Margin	0.08	0.10	0.08	0.07	0.08	0.04	0.08	0.04

Adjusted Net Income	176.33	272.97	327.95	407.98	485.62	182.30	408.91	105.59
% Margin	0.05	0.07	0.07	0.06	0.07	0.03	0.08	0.02

Adjusted Basic EPS	0.34	0.56	0.62	0.77	0.91	0.35	0.77	0.20

Подтверждающие расчеты

Income Statement

Balance Sheet

Statement of Cashflows


Income Statement
						Original
CNY	Fiscal Year Ending					Latest	Year-to-date Ending
(in millions)	Dec-19	Jan-21	Dec-21	Dec-22	Dec-23	Sep-24	Sep-23	Sep-24
	FY - 4	FY - 3	FY - 2	FY - 1	FY	LTM	YTD-1	YTD

Revenue	3,265	3,913	4,874	6,296	6,872	6,927	5,169	5,225
% Growth	NA	19.8%	24.6%	29.2%	9.1%			1.1%

Cost of Revenue	(2,692)	(3,282)	(4,175)	(5,452)	(6,319)	(6,621)	(4,537)	(4,840)
Gross Profit	573	631	699	844	553	306	632	385
% Revenue	17.5%	16.1%	14.3%	13.4%	8.0%	4.4%	12.2%	7.4%

Research and Development	(49)	(83)	(95)	(129)	0	(11)	(61)	(72)
Selling and Marketing	(149)	(45)	(55)	(59)	0	12	(46)	(34)
General and Admin	(120)	(146)	(156)	(190)	0	2	(116)	(114)
Other Inc / (Exp)	11	5	19	40	10	(79)	43	(46)
Total Operating Exp	(307)	(269)	(287)	(338)	10	(76)	(180)	(266)

Operating Income	266	362	412	506	563	230	452	119
% Revenue	8.2%	9.3%	8.4%	8.0%	8.2%	3.3%	8.7%	2.3%

Interest Expense	(56)	(50)	(14)	(4)	0	(64)	19	(45)
Pre-tax Income	211	313	398	502	563	166	471	74
Earnings of Discontinued Ops.	0	0	0	0	0	0	0	0
Provision for Taxes	(21)	(46)	(47)	(66)	(77)	(51)	(55)	(29)
Net Income to Company	190	266	351	436	486	115	416	45
% Margin	5.8%	6.8%	7.2%	6.9%	7.1%	1.7%	8.0%	0.9%

Minority Interest in Earnings	4	2	1	(2)	0	35	(18)	17
Net Income to Stockholders	194	268	352	434	486	150	398	63

Preferred Dividends	0	0	0	0	0	0	0	0
Other Adj.	0	0	0	0	0	0	0	0

Net Income to Common	194	268	352	434	486	150	398	63
% Margin	5.9%	6.8%	7.2%	6.9%	7.1%	2.2%	7.7%	1.2%

As Reported
Basic EPS (Continuing Ops)	0.38	0.55	0.67	0.81	0.91	0.28	0.75	0.12
Diluted EPS (Continuing Ops)	0.38	0.53	0.67	0.81	0.91	0.28	0.75	0.12

WA Basic Shares Out.	513.59	483.29	528.51	532.75	532.01	522.59	531.14	521.72
WA Diluted Shares Out.	513.59	507.57	528.51	532.75	532.01	522.59	531.14	521.72

EBITDA, EBIT Reconciliation
EBT, Incl. Unusual Items	211	313	398	502	563	166	471	74
Addback: Net Interest Expense	56	50	14	4	0	64	(19)	45
Addback: Other Non Operating Expenses, Total	(3)	7	(2)	(19)	(10)	(10)	(12)	(12)
Addback: Depreciation & Amortization	89	112	131	145	145	36	108	0
Addback: Restructuring Charges	0	0	0	0	0	0	0	0
Addback: Merger / Acquisition Expenses	0	0	0	0	0	0	0	0
Addback: Goodwill Impairment	0	0	0	0	0	0	0	0
Addback: Gain (Loss) On Sale Of Invest.	0	0	(1)	5	0	(4)	3	(1)
Addback: Gain (Loss) On Sale Of Assets	(1)	0	(0)	(1)	0	0	(0)	0
Addback: Asset Writedown	2	9	11	1	0	95	(12)	83
Addback: In Process R&D Expenses	0	0	0	0	0	0	0	0
Addback: Insurance Settlements	0	0	0	0	0	0	0	0
Addback: Legal Settlements	0	0	0	0	0	0	0	0
Addback: Other Unusual Items	(20)	0	(41)	(43)	0	0	0	0
Adjusted EBITDA	334	491	510	593	697	348	538	188
% Margin	10.2%	12.5%	10.5%	9.4%	10.1%	5.0%	10.4%	3.6%

Adjusted EBIT	245	378	379	449	553	312	430	188
% Margin	7.5%	9.7%	7.8%	7.1%	8.0%	4.5%	8.3%	3.6%

Adjusted Net Income Reconciliation
Net Income to Company	190	266	351	436	486	115	416	45
Addback: Unusual Items	(18)	9	(31)	(38)	0	91	(10)	82
Less: Tax Benefit of Unusual Items (26%)	5	(2)	8	10	0	(24)	3	(21)
Adjusted Net Income	176	273	328	408	486	182	409	106
% Margin	5.4%	7.0%	6.7%	6.5%	7.1%	2.6%	7.9%	2.0%

Ошибка загрузки

Chenguang Biotech Group

SZSE:300138

Китай / Производители товаров масс. потребления / Продукты питания

Финансовая отчетность за 5 лет